The n e w e n g l a n d j o u r n a l of m e d i c i n e Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

on survival, conducted the Alpha-radin in Symptomatic Prostate Cancer Patients (ALSYMPCA) study, a phase 3, randomized, dou-ble-blind, multinational study comparing the efficacy and of versus in patients with castration-resistant prostate cancer and bone metastases.

[1]  C. Parker,et al.  A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. , 2013, European urology.

[2]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[3]  D. Goldman,et al.  Timing is everything: time to ADT and chemotherapy initiation for treatment of metastatic prostate cancer , 2012 .

[4]  D. Goldman,et al.  Treating people right: Who goes untreated with systemic therapy for metastatic prostate cancer (mPC)? , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Staffurth,et al.  A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. , 2012, European journal of cancer.

[6]  D. Goldman,et al.  Treating people right: Who goes untreated with systemic therapy for metastatic prostate cancer (mPC)? , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  C. Parker,et al.  A population-based study of prostate cancer chemotherapy. , 2011, Clinical oncology (Royal College of Radiologists (Great Britain)).

[8]  O. Sartor,et al.  Stromal targeted therapy in bone metastatic prostate cancer: promise delivered. , 2011, Asian journal of andrology.

[9]  O. Sartor,et al.  Stromal targeted therapies in prostate and renal cancer: new concepts and knowledge. , 2011, Clinical genitourinary cancer.

[10]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[11]  O. Sartor.  Potential synergistic implications for stromal-targeted radiopharmaceuticals in bone-metastatic prostate cancer. , 2011, Asian journal of andrology.

[12]  M. Carducci,et al.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.

[13]  J. Machiels,et al.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.

[14]  A. Lipton.  Implications of bone metastases and the benefits of bone-targeted therapy. , 2010, Seminars in oncology.

[15]  K. Liepe.  Alpharadin, a 223Ra-based alpha-particle-emitting pharmaceutical for the treatment of bone metastases in patients with cancer. , 2009, Current opinion in investigational drugs.

[16]  X. Mariette,et al.  Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  C. Parker,et al.  Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. , 2007, The Lancet. Oncology.

[18]  S. Nilsson,et al.  High-Linear Energy Transfer Irradiation Targeted to Skeletal Metastases by the α-Emitter 223Ra: Adjuvant or Alternative to Conventional Modalities? , 2006, Clinical Cancer Research.

[19]  I. Finlay,et al.  Radioisotopes for the palliation of metastatic bone cancer: a systematic review. , 2005, The Lancet. Oncology.

[20]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[21]  G. Roodman.  Mechanisms of bone metastasis. , 2004, Discovery medicine.

[22]  J. Roeske,et al.  Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  C. Kerr.  (223)Ra targets skeletal metastases and spares normal tissue. , 2002, The Lancet. Oncology.

[24]  G. Henriksen,et al.  Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. , 2002, Cancer research.

[25]  E. Silberstein.  Systemic radiopharmaceutical therapy of painful osteoblastic metastases. , 2000, Seminars in radiation oncology.

[26]  R. Vessella,et al.  Mechanisms, Hypotheses and Questions Regarding Prostate Cancer Micrometastases to Bone , 1998, Cancer and Metastasis Reviews.

[27]  J. Humm,et al.  Radioimmunotherapy with alpha-emitting nuclides , 1998, European Journal of Nuclear Medicine.

[28]  S. Adami.  Bisphosphonates in prostate carcinoma , 1997, Cancer.

[29]  K. K. Lan,et al.  Discrete sequential boundaries for clinical trials , 1983 .

[30]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[31]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.

[32]  J. Nelson,et al.  Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy--Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[33]  V. Lewington,et al.  Bone-seeking radionuclides for therapy. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  S. Fosså,et al.  First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.